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Creatine transporter (CrT) deficiency is an X-linked intellectual disability caused by mutations of CrT. Aim:
This work focus on the preclinical development of a new therapeutic approach based on a microemul-
sion (ME) as drug delivery system for dodecyl creatine ester (DCE). Materials & methods: DCE-ME was
prepared by titration method. Novel object recognition (NOR) tests were performed before and after
DCE-ME treatment on Slc6a8-/y mice. Results: Intranasal administration with DCE-ME improved NOR per-
formance in Slc6a8-/y mice. Slc6a8-/y mice treated with DCE-ME had increased striatal ATP levels mainly in
the striatum compared with vehicle-treated Slc6a8-/y mice which was associated with increased expres-
sion of synaptic markers. Conclusion: These results highlight the potential value of DCE-ME as promising
therapy for creatine transporter deficiency.
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Creatine transporter deficiency (CTD) is an X-linked inherited metabolic disorder caused by loss-of-function
mutation in the SLC6A8 gene encoding the creatine transporter (CrT). The CrT is responsible for the entry of
creatine (Cr) into cells andmutations inCrT result in reductions of brainCr. Individuals withCTDhavemoderate to
severe intellectual disability, behavioral disorder such as attention deficit, hyperactivity disorder or autistic behavior
and occasionally epilepsy [1–3]. CTD is a rare disorder, though it may be underdiagnosed due to the similarities
between CTD and other autistic-like disorders. There are currently (October 2018) 383 cases of individuals with
SLC6A8 variants listed on a dedicated online database (https://databases.lovd.nl/shared/variants/SLC6A8). The
estimated exome variant server database suggest that there are approximately 35,000 female CTD variants in the
USA [4]. To date, there are no treatments available for CTD as oral creatine administration is ineffective. The
primary role of Cr is to buffer energy levels in high energy consuming cells, particularly those of the brain, heart
and muscle. In a reversible reaction catalyzed by Cr kinase, a phosphate group from ATP generated by oxidative
phosphorylation or glycolysis is transferred to Cr to form pools of phospho-Cr. The phosphate group could then
be transferred to ADP at the sites of ATP consumption, providing rapid energy replenishment. The importance of
Cr in maintaining ATP levels is shown by the reduction of brain ATP in Slc6a8-/y mice [5]. The reductions in ATP
could have wide implications for cellular function and may be responsible for several of the observed phenotype in
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CTD patients. Indeed, Cr and phospho-Cr have been linked to neuronal morphology and the uptake of glutamate
into synaptic vesicles [5,6]. In addition to its role as energy reserve, creatine can protect against excitotoxicity as well
as against β-amyloid toxicity in vitro. Creatine produced dose-dependent neuroprotective effects against (1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine) MPTP toxicity reducing the loss of dopamine within the striatum and the
loss of dopaminergic neurons in the substantia nigra [7,8]. Due to its neuroprotective effects, creatine is now in
clinical trials for the treatment of Parkinson’s disease. This neuroprotective and neuromodulatory effects that may
be independent of its energetic role could contribute to the neurologic symptoms of CTD [7].
As the cause of CTD is obvious – the brain lacks Cr – therapeutic strategies should focus on increasing
Cr and phospho-Cr stores in the brain. Improvements in cognitive ability and quality of life are achieved in
individuals with disorders of Cr synthesis following Cr supplementation. However, the inability of Cr to cross
the blood–brain barrier (BBB) without the functional CrT presents a unique challenge in CTD. In order to
get Cr into the brain, the BBB must be circumvented or the brain must be stimulated to synthesize Cr itself.
Since the Cr synthesis enzymes Arginine: Glycine Amidinotransferase (AGAT) and Glycine Amidinotransferase
(GAMT) are expressed in the brain, few studies were conducted in which CTD patients were supplemented with
Cr synthesis precursor’s arginine, methionine and glycine [9]. There were no appreciable increases in brain Cr levels
or cognitive ability in these patients though the combination therapy did halt the progression of symptoms in some
patients. [10,11]. This would suggest that the only viable treatment strategy for CTD is to circumvent the BBB
through Cr derivates or by masking the polar ends of Cr. The Cr mimetic cyclocreatine (cCr) is a planar molecule
that can be phosphorylated/dephosphorylated by Cr kinase, though it should be noted that the reaction favors
phospho-cCr over cCr. This makes cCr a poorer phosphate donor compared with Cr. Using Camk2a-Cre, mice
lacking Slc6a8 in forebrain neurons showed cognitive deficits compared with wild-type mice. These deficits were
ameliorated following 9 weeks of cCr supplementation [12]. While this study shows promise, the limitations of cCr
as a phosphate donor necessitate improved treatment strategies which focus on replacing the endogenous Cr in the
brain. A possible treatment strategy for CTD is to use lipophilic Cr derivatives which could then be cleaved to Cr
in the brain [13]. Based on structure–activity relationship, dodecyl creatine ester (DCE) is one of the most likely Cr
derivatives to be incorporated into the brain [13]. Accordingly, DCE crossed brain endothelial cells and was able to
diffuse through the in vitro rat primary cell-based BBB and into neurons. Increased Cr content was observed in
fibroblasts from CTD patients incubated with DCE [14]. Together, this makes DCE an ideal leader molecule for in
vivo testing. However, there is concern that degradation of DCE by somatic esterases would prevent a significant
accumulation of Cr in the brain. Therefore, the development of an efficient drug delivery system is required. To
address this, we developed an optimized microemulsion (ME) based on approved US FDA excipients to improve
DCE delivery and membrane transport. The ME system may offer protection from chemical and enzymatic
degradation [15,16]. Further, we utilized intranasal administration as it holds great potential for nose-to-brain drug
delivery. The purpose of this study was to determine if this treatment strategy could increase brain Cr and improve
cognitive function in ubiquitous Slc6a8-/y mice. These mice have significant cognitive deficits, as evidenced by
poor spatial learning and memory, decreased novel object recognition (NOR) memory and reduced conditioned
fear memory [17]. The results of this study show that short-term treatment of Slc6a8-/y mice with DCE either
by intracerebroventricular or by IN administration of DCE-ME improved NOR performance. This suggests that
DCE-ME could be a promising candidate for the treatment of CTD.
Materials & methods
Materials
DCE was synthesized as described previously [13]. Creatine monohydrate, creatine (methyl-D3) monohydrate (Cr-
d3) and docosahexaenoic acid (DHA) were from Sigma (St Quentin-Fallavier, France). Glyceryl monolinoleate
(Maisine R© CC), highly purified diethylene glycol monoethyl ether (Transcutol R© HP) were from Gattefosse´ (Nan-
terre, France). Purified water was from Milli-Q R© Advantage A10 System (Merck Millipore, Fontenay-sous-Bois,
France) and ammonium acetate fromProlaboVWR International (Fontenay-sous-Bois, France). All other chemicals
and solvents were from Sigma–Aldrich (Saint-Quentin-Fallavier, France) and used without further purification.
Solubility study
The solubility of DCE in the ME components was determined by adding excess drug to 1 g of each selected oil,
surfactant/co-surfactant or a mixture of them in Eppendorf R© tubes. The tubes were maintained at 37 ± 1◦C in a
shaker (Thermomixer C, Eppendorf, Montesson, France) for 48 h to attain equilibrium. Samples were centrifuged
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(Thermo Fisher Scientific, Villebon-sur-Yvette, France) at 20,000 g for 5 min and the supernatant was filtered
through a 0.22 μm filter (Sartorius, Goettingen, Germany) and analyzed in triplicate by LC-MS/MS.
DCE loaded MEs
The optimized ME formulation comprised 63% w/w Transcutol R© HP and 25% w/w of water. The oil concentra-
tion was maintained at 12% w/w and comprised DHA and Maisine R© CC (2:1% w/w). The specified amount of
DCE was first dissolved in the oil phase, and the excess of nonsolubilized drug was removed by centrifugation at
20,000 g for 5 min. Then, the surfactant was added to the oily phase with magnetic stirring at room temperature
(Stuart CB162, Bibbly Scientific, Nemours, France). Finally, a fixed amount of distilled water was added dropwise
to the above mixture and stirred continuously until transparent and homogeneous ME were produced.
Pseudo ternary phase diagram
Pseudo ternary phase diagrams of oil, surfactant and water were constructed using the water titration method [18]
to determinate the feasibility domain for ME formation. Maisine R© CC was blended with DHA (forming the oily
phase) in fixed weight ratios (1:1 and 2:1). Oily phase and surfactant were mixed at room temperature (25◦C)
at predetermined ratios (w/w) and ultra-purified water was added dropwise to each oily phase-surfactant mixture
with continuous magnetic stirring. After equilibrium, the samples were visually checked and determined as being
clear transparent ME. The phase diagrams were plotted using Statgraphics Centurion 18 software (Statgraphics
Technologies, VA, USA).
Physico-chemical characterization
The size distribution and surface charge of the prepared nanocarriers were analyzed using a Vasco Flex nanoparticle
size analyzer (Cordouan Technology, Pessac, France). Sample suspensions were diluted in deionized water to ensure
convenient scatter intensity on the detector. The average hydrodynamic diameter, the polydispersity index and the
ζ potential were determined at 25◦C in triplicate. The pH of the final formulation was measured using an Inolab
pH730 (WTW, Weilheim, Germany).
Transmission electron microscopy
The morphology of ME was studied using an LVEM5 transmission electron microscope (Cordouan Technologies,
Pessac, France). Before analysis, samples were diluted with ultrapure water (1:50) and an ELMO glow discharge
system for EM grids was applied following the manufacturer’s protocol.
Storage stability
The stability of all the formulations was evaluated under storage conditions for 15 days at 4–8◦ C. Three sets of
parameters were assessed at different time points: macroscopic appearance (presence of aggregated, cream formation,
changes in color); particle size, polydispersity index and ζ potential; and leakage of DCE from the formulation.
DCE quantification in ME formulation
Drug loading was determined after sample centrifugation at 20,000 g for 5 min in a Sorvall ST 16R Centrifuge
(Thermo Scientific, Villebon-sur-Yvette, France). Three samples of supernatant were prepared by dissolution of an
exact quantity of ME dispersion in acetonitrile-1% formic acid. Chromatography was performed using a binary
pump LC-30AD (Shimadzu Nexera X2, Paris, France) with a 2.0 × 150 mm Uptisphere Diol HPLC column
(UP6OH, Interchim, Montluc¸on, France). The mobile phase consisted of 0.1% formic acid solution (A) and
acetonitrile containing 0.1% formic acid (B) in isocratic mode at 20/80 (A/B) with a flow rate of 0.4 ml/min.
Analyte (10 μl) was injected onto the column placed in an oven at 40◦C. The total runtime was 6 min. Detection
was done by MS/MS (Finnigan TSQ Quantum Discovery with Xcalibur and LCquan softwares, Thermo) in
positive electrospray mode. Spray voltage was 3.0 kV and sheath and auxiliary gas pressures were 50 and 20
(arbitrary units), respectively. The in-source CID energy was fixed at 12 V and capillary temperature was 350◦C.
Tube lens and collision energy values were optimized for DCE compounds. The standard curves showed linearity
over a range of 10–1000 ng/ml.
Stability in brain homogenates.
The homogenates from WT mice were obtained using a VCX 130 Ultrasonic processor (Sonics, CT, USA) with
a 60-s program with a net power output of 130 W. The DCE-ME was mixed with brain homogenate (dilution
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1:10) and the mixtures were incubated at 37◦C in a Thermomixer C (Eppendorf, Montesson, France) with the
shaker speed set at 900 rpm. At predetermined time points (0, 0.25, 0.5, 1, 2 and 3 h), 100 μl of samples were
collected and the extraction protocol applied for Cr quantification was used. The quantifications in LC-MS/MS
were carried out as described above for DCE-ME. All the samples were assayed in triplicate.
Animals
Slc6a8-/y mice were generated and genotyped in-house according to published studies [5,17,19]. These mice were
generated on a C57Bl/6 J background and have been maintained on this background since their generation. For
the IN treatment study, mice were assigned groups using a random-number table. No more than one mouse/group
was used from a litter. All experimental protocols were approved by the CCRF Institutional Animal Use and Care
Committee and the facility is IACUC-approved. The experiments were performed using 91 male mice of 18–25
weeks old.Male mice were used due to the X-linked nature of CTD.Mice were housed under standard experimental
conditions: room temperature (20 ± 2◦C); light/dark cycle (14 h light/10 h dark); water and food ad libitum,
and kept in social groups of four mice per cage. To minimize circadian rhythm influence, all behavioral testing
was performed between 0900 and 1300 h. After testing was completed, mice were sacrificed according to ethical
guidelines.
DCE-intracerebroventricular treatment
Mice were deeply anesthetized, placed in a stereotaxic frame and fitted with an (intracerebroventricular) ICV
cannula, which was fitted to catheter tubing (Brain Infusion Kit 3, Alzet). The coordinates for cannula placement
to target the lateral ventricle were (from bregma): A/P = +0.3 mm;M/L = -1.0 mm; D/V = -3.0 mm. The cannula
was primed with the treatment compound prior to implantation. The tubing was guided under the dorsal dermis
and a port was created between the shoulder blades. Following recovery (24–48 h), Slc6a8-/y mice were treated once
daily for 5 days with either DCE (0.02 mg/g bodyweight/day) or vehicle (VEH) while Slc6a8+/y mice were only
treated with VEH. Mice were transferred to a holding room and a syringe with a blunt end needle was attached to
the port and 20 μl of compound was infused at a rate of 1 μl/min.
IN administration of DCE-ME treatment
As there were no significant differences in NOR performance in the previous cohort, mice were randomized prior to
assignment to treatment groups. Using a P10 micropipette, 6 μl of DCE-ME or VEHwas placed in the nostril. The
intracerebroventricular treatment (DCE)-ME (4 mg/g) or VEH was given twice bilaterally (24 μl total volume)
for each dose for 10 days.
Novel object recognition
Mice were tested in the ANY-box apparatus (Stoelting Company, IL, USA). Testing began on the fifth day of
treatment and concluded on the last day of treatment. First, mice were habituated to an empty arena (41 × 41 cm)
for 2 days (10 min/day) and then habituated to two identical objects in the chamber (10 min/day) for the following
2 days. On the fifth day, animals were presented with two new identical objects until 30 s of cumulative observation
time between the objects was obtained. Total 1 h later, memory was tested by presenting the animal with an
identical copy of one of the familiar objects along with a novel object and tested identically to the familiarization
trial. Time exploring the object was defined as entry into a 2-cm zone around the object. Performance was measured
by an experimenter who was blinded to the treatment. A discrimination index was calculated where the time spent
observing the novel object was subtracted from the time spent observing the familiar object and then divided by
the total time of exploration.
Cr quantification in brain sample
Sample preparation
Before analysis, 0.2 g of water containing protease (5 X) and phosphatase (25 X) inhibitor cocktails (Roche,
Boulogne-Billancourt, France) was added to different brain tissues to ensure that protein extracts did not degrade
before analysis for targets of interest. The homogenates were obtained using a VCX 130 Ultrasonic processor
(Sonics, CT, USA) with a 60-s program with a net power output of 130 W. From each brain sample, three separate
aliquots were diluted 1:50 in the same cocktail mix and fortified with 10 μl of internal standard (IS) working
solution containing 0.5 μg/ml creatine-d3 in water. Precooled 1% formic acid-acetonitrile (400 μl) was added and
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each sample was vortex mixed for 30 s before 10 min of centrifugation at 10,000 g, 4◦C in aMegafuge 16RHeraeus
centrifuge (Thermo Fisher Scientific, Villebon-sur-Yvette, France). Sample supernatants were transferred to a clean
set of tubes, placed in a 40◦C water bath and evaporated to dryness under a 10–15 psi air stream in a TurboVap LV
Evaporator (Biotage, Lund, Sweden). Sample residues were reconstituted in 200 μl of water/acetonitrile (50:50)
1% formic acid, vortex mixed for 30 s and centrifuged for 5 min at 10,000 g before transfer to vials.
Preparation of stock & working solutions
Stock solution containing 7.62 mM Cr was prepared in 1% formic acid solution. This stock solution was equally
diluted in acetonitrile/water (95/5) 1% formic acid yielding eight working solutions (WS) from 2 to 45 μM for Cr.
These working solutions were used to prepare the calibration standards (CS). Brain homogenate CSs and quality
controls were prepared in duplicate by adding 10 μl of the corresponding WS to 90 μl of blank matrix and, after
gentle vortexing, by adding 10 μl of the IS solution. This resulted in eight CSs containing Cr from 0.2 to 0.45 μM.
Brain homogenate CSs and quality control samples were processed according to the previously described sample
preparation method.
Chromatographic conditions & mass spectrometric parameters
The LC-MS/MS system consisted of a binary pump LC-30AD (Shimadzu Nexera X2) coupled to a triple
quadrupole mass spectrometer TSQ Quantum Ultra (Thermo Scientific, Villebon-sur-Yvette, France). Analytes
was ionized using electrospray ion source in positive mode. Chromatographic separation was achieved at 40◦C via
gradient elution of 10 mM buffer ammonium acetate (AA) pH 10 versus acetonitrile at a flow rate of 0.4 ml/min
on an ACQUITY UPLC BEH Amide column (130 A˚, 1.7 μm, 2.1 × 150 mm) with guard column provided by
Waters (Saint-Quentin-en-Yvelines, France). The autosampler temperature was maintained at 4◦C and the injection
volume was 10 μl. The total runtime was 6 min. MS/MS conditions were established by infusing different diluted
solutions of Cr, and Cr-d3, in the mass spectrometer in positive ionization mode. Data were acquired by MRM
(multiple reaction monitoring) mode and the voltage ion spray was fixed at 3 kV. Quantification was performed
using the transition m/z: 132.141→90.054 (CE = 15 V, tube lens = 60), lens = 57) for Cr.
Data analysis
The LCquan software (Thermo Electron Corporation) was used for method development, data collection and
extracted peak integration. Linearity of the calibration curves was assessed by least-squared linear regression after
normalization of the x- (concentration ratio of the analyte to the IS) and y-axis (peak area ratio of the analyte vs the
IS) using the decimal logarithm. The method, which is intended for use during fundamental research, was validated
using criteria adapted from the US FDA guidance. The amount of Cr was standardized to the amount of protein
in each homogenate tissue by the Bradford technique following the manufacturer’s instructions (Sigma–Aldrich,
France).
Gene expression assessment by total RNA extraction & real-time quantitative PCR
The impact of brain Cr levels on gene expression of LTP biomarkers was determined by measuring mRNA levels
of selected genes, BDNF, C REB, PS95, in brain tissues from treated and control Slc6a8-/y mice. Total RNA was
extracted with QIAzol lysis reagent (Qiagen #79306) into Precellys lysing tubes and purified on RNeasy R© Plus
Universal minikit columns (Qiagen, Courtaboeuf, France #1062832). Briefly, brain tissues were lysed with 0.5 ml
of QIAzol R© reagent by pipetting. After addition of 100 μl of chloroform, mixtures were centrifuged at 10,000 g
for 15 min at 4◦C, supernatants mixed with 600 μl of 70% ethanol and loaded onto RNeasy R© columns (Qiagen,
Courtaboeuf, France). Total RNA was washed and eluted with RNase-free water according to the manufacturer’s
protocol and stored at -80◦C. RNA concentration was measured spectrophotometrically at 260 nm in a NanoDrop
2000c (Thermo Scientific, Villebon-sur-Yvette, France; sample A260 nm/A280 nm ratios over 1.8 indicated
reduced genomic DNA contamination). cDNAs were synthesized from 0.5 μg of total RNA with RT2 First Strand
kit (Qiagen, Courtaboeuf, France #330411) according to the manufacturer’s protocol and stored at -80◦C. For
qPCR, 9 ng of cDNA was mixed with 6.25 μl of iQ SYBR Green Supermix (Biorad #172-5124) and completed
to 12 μl with milli-Q water. Mixes were loaded onto customized Hard-Shell R© 96-Well PCR Plates (Bio-Rad
#HSP9601) containing 0.3 μM of specific primers of each gene and the qPCR reactions were performed in a
7900HT Fast Real-Time PCR System (Applied Biosystems, Villebon-sur-Yvette, France) with the following cycle
conditions: 95◦C for 10 min, 40 cycles of 15 s at 95◦C followed by 1 min at 60◦C and finished by 30 s at 72◦C.
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Table 1. Physico-chemical characterization of dodecyl creatine ester loaded-microemulsion.
Time (days) Size (nm) PI  potential (mV) Loading (mg/g)
0 137.9 ± 7.2 0.09 17.6 ± 2,3 3.9 ± 0.05
7 128.0 ± 12.5 0.06 16.8 ± 4.7 3.5 ± 0.2
15 148.8 ± 1.8 0.08 19.8 ± 0.7 3.0 ± 0.02
Data are shown as mean ± standard deviation (n = 3).
PI: Polydispersity index.
Threshold cycles (Ct) of target gene and cyclophilin A (Ppia as control housekeeping gene) were recorded and gene
expression was calculated as 2-Ct (Ct = Ct treated - Ct control, Ct = Ct target - Ct Ppia). Specificity
of PCR reactions was confirmed by melting curve analysis.
ATP assay
Slc6a8-/y and Slc6a8+/y micewere decapitated following brief isofluorane anesthesia. The five brain regions (olfactory
bulb, cerebellum, hippocampus, cortex and striatum) were dissected and rapidly frozen in dry ice-cooled isopentane.
Samples were weighed and homogenized in an equal volume of perchloric acid. ATP levels were analyzed using
a commercially available fluorescence kit (Abcam Cambridge, MA, USA). ATP levels were normalized to tissue
weight. Percent control levels were determined by dividing all samples by the mean of the Slc6a8+/y mice for the
specific tissue studied.
Statistics
All statistical analyses were performed using GraphPad Prism software (Version 7.0). Experimental comparisons
with multiple groups were analyzed using one-way ANOVA with either the two-stage linear step-up procedure of
Benjamini, Krieger and Yekutieli used for post hoc analysis or with the Tukey’s multiple comparison test for post
hoc analysis. For comparison of two groups, two-tailed Student’s or Mann–Whitney tests were performed and are
noted in the figure captions. A p-value of 0.05 or less was considered statistically significant.
Results
Rational design & physico-chemical characterization of DCE-ME
We examined the design of versatile oil in water (O/W)ME prepared by the titration method and composed of US
FDA-approved excipients which could enhance DCE solubility and thus improve its bioavailability. Furthermore,
the lipophilic nature and the nanometric globular size of this system could account for the improvement in the
absorption across the mucosal membranes [16].
The solubility of DCE was determined individually in a full lipids list at 2% w/w concentration. DCE had the
highest solubility in glyceryl monolinoleate (Maisine R© CC), and hence this lipid was employed in the preparation
of ME. The criteria for selection of surfactant/cosurfactant were safety considerations, effective concentrations and
preferably nonionic type. Among the tested surfactants and co-surfactants, the solubility of DCE was the highest
in highly purified diethylene glycol monoethyl ether (DEGMEE; Transcutol R© HP; 7.5 ± 0.5 mg/g) and thus
this excipient was chosen for further studies. It should be pointed out that DEGME also acts as a permeation
enhancer Figure 1 [20]. A summarizes the process of the rational design of our ME. Pseudoternary phase diagrams
with different oil phase and surfactant compositions were constructed to determine the feasibility domain for ME
formation (Figure 1B). DHA-rich oil, being a long chain triglyceride, exhibited poor penetration into the surfactant
monolayer and showed a small ME region (data not shown). Thus, a combination of DHA with Maisine R© CC (a
mixture of mono-, di- and triglycerides of mainly linoleic and oleic acids) was evaluated at the ratios of 1:1 and 2:1,
respectively. The ME region was identified as the area where clear and transparent formulations were observed and
this area increased with increasing ratio of Transcutol R© HP. However, at a surfactant concentration above 70%, the
ME system formed a viscous gel. In fact, by increasing the surfactant concentration to a certain extent results in an
enhanced water penetration into the oil droplets, causing interfacial disruption and ejection of oil droplets into the
aqueous phase [21]. From the ternary plots, it was shown that the ME region at oil ratio DHA: Maisine R©CC (2:1)
was maximum when compared with 1:1, and thus this ratio was chosen and the oil content fixed at 12% in the
final formulation. A stable monodispersion of about 130–150 nm particle size (IP ≤0.2) was obtained with pH of
4 ± 0.1 and positive ζ potential which accounts for its in vivo cellular uptake (Table 1). The presence of a relatively
high ζ potential value led to stable nanodispersions and overcame the tendency of aggregation due to van der Waals
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Figure 1. Rational design of DCE-ME strategy. (A) Schematic representation of microemulsion (ME) preparation.
Solubilization of DCE in the inner lipid phase (Maisine R©CC/DHA); surfactant addition (Transcutol R© HP) under
magnetic stirring; water titration to the previous mix and ME spontaneous formation; the final structure of the ME: a
lipid inner phase in which DCE was previously solubilized surrounded by a surfactant shell and the external aqueous
phase. (B) Ternary phase diagrams indicating o/w microemulsion region at different surfactant/oil/water mix ratios.
Oil: Maisine R©CC:DHA (1:1); oil: Maisine R©CC:DHA (1:2). (C) Transmission electron microscopy micrograph of optimized
DCE loaded ME.
DCE: Dodecyl creatine ester.
attraction forces. Moreover, nanosized droplets present greater surface area and high free energy, assuring faster and
greater drug permeation through absorption barriers such as mucosal surfaces [22]. DCE was incorporated in ME
with a loading of about 4 mg/g dispersion without the use of organic solvents. Moreover, no leakage of loaded
DCE was observed after 15 days at storage conditions (4–8◦C) (Table 1). The TEM photograph in Figure 1C also
revealed the morphological characteristics of spherical oil droplets on the nanoscale in loaded ME.
To evaluate the stability of DCE-ME and its potential to turnover into Cr, we mimicked the in vivo conditions
once the formulation reaches the brain. For this, we incubated DCE-ME in a brain mouse homogenate for 3 h at
37◦C with gentle stirring and at different time points, we quantified the remaining DCE. We found that following
15 min of incubation, about 30% of the initial amount of DCE was found in the homogenate which means
that DCE could be converted into Cr by the esterases from brain cells and available to restore the Cr pool. This
hypothesis is supported by the increases in brain creatine content in the Slc6a8-/y mice model.
The remaining DCE could be attributed to the molecules that are deep in the core of the lipidic phase of the
ME and thus delivered slowly. These results are in accordance with our previous finding concerning the conversion
of DCE into Cr in human fibroblast cells [14].
Intracerebroventricular DCE treatment increases brain creatine content & rescues synaptic &
cognitive deficits of Slc6a8-/y mice
Consistent with human CTD, Slc6a8-/y mice have reduced brain Cr content and cognitive deficits [17]. Slc6a8-/y
mice also have reduced body mass and a near absence of Cr in most tissues, including the muscle [17,23]. This mouse
model was used to test the efficacy of ICV-administered DCE compared with wild-type (WT) Slc6a8+/y mice used
as control. It should be pointed out that DCE did not contribute to the mortality or morbidity of Slc6a8-/y mice.
Prior to treatment, mice were tested in the NOR test. Consistent with previous findings, Slc6a8-/y mice showed
object recognition deficits when compared with Slc6a8+/y mice (t31 = 2.35, p < 0.05). Mice were assigned to
treatment groups by sorting animals based on discrimination index and alternating assignments between vehicle
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Figure 1. Rational design of DCE-ME strategy (cont.). (A) Schematic representation of microemulsion (ME) preparation. Solubilization of
DCE in the inner lipid phase (Maisine R©CC/DHA); surfactant addition (Transcutol R© HP) under magnetic stirring; water titration to the
previous mix and ME spontaneous formation; the final structure of the ME: a lipid inner phase in which DCE was previously solubilized
surrounded by a surfactant shell and the external aqueous phase. (B) Ternary phase diagrams indicating o/w microemulsion region at
different surfactant/oil/water mix ratios. Oil: Maisine R©CC:DHA (1:1); oil: Maisine R©CC:DHA (1:2). (C) Transmission electron microscopy
micrograph of optimized DCE loaded ME.
DCE: Dodecyl creatine ester.
and treatment to avoid performance confounds. Accordingly, there were no pretreatment differences between
Slc6a8-/y mice when analyzed by treatment group (t22 = 0.94, p = 0.353). Following ICV administration, there
was a significant effect of group (F[2,21] = 7.035, p < 0.001) with post hoc analysis showing that DCE-treated
Slc6a8-/y mice did not differ from control mice (p = 0.283). Vehicle-treated Slc6a8-/y mice showed reductions in
object recognition as well as in Cr brain content in striatum, cortex, hippocampus and cerebellum tissues compared
with both Slc6a8+/y and DCE-treated Slc6a8-/y mice (p < 0.05) (Figure 2A & B) even if there is some overlap in
the lower quartile of the DCE-treated Slc6a8-/y versus the upper quartile of the Vehicle-treated Slc6a8-/y mice. The
overall effect was that there was an increase in mean Cr levels. The results of the experiment show no toxic effect
of DCE, suggesting the safety of this compound.
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Figure 2. Improved object recognition memory in
Slc6a8-/y mice and creatine content in different brain
regions after intracerebroventricular treatment with
dodecylcreatine ester. (A) Novel object recognition tests
were conducted 1 h after familiarization in Slc6a8-/y and
Slc6a8+/y (n = eight animal/group) mice treated for 5
days with vehicle or DCE. The discrimination index was
calculated as the difference between new and familiar
object exploration times divided by total time spent
observing both objects. Experimental comparisons with
multiple groups were analyzed using a one-way ANOVA
with the false discovery rate method of Benjamini,
Kreiger and Yekutieli used for post hoc analysis. Data are
mean ± standard error of the mean. (B) Creatine content
in different brain regions of Slc6a8+/y and Slc6a8-/y mice
(n = 4) after intracerebroventricular administration of
DCE measured by LC-MS/MS. Data are mean ± standard
error of the mean. Mann–Whitney test.
*p ≤ 0.05.
DCE: Dodecylcreatine ester.
Table 2. ATP levels in brain regions of Slc6a8-/y mice after nasal administration of dodecylcreatine ester-microemulsion.
Experimental conditions ATP values (nMol/mg tissue wgt; mean ± SEM)
Striatum Hippocampus Olfactory bulb Cortex Cerebellum
Slc6a8+/y 58.0 ± 7.3 270.5 ± 38.8 91.1 ± 13.6 47.1 ± 9.6 738.9 ± 99.4
Slc6a8-/y VEH 6.8 ± 1.4†,‡ 13.1 ± 1.0† 52.8 ± 11.9† 26.6 ± 6.9 36.1 ± 4.5†
Slc6a8-/y DCE-ME 39.3 ± 10.3 12.0 ± 1.9† 52.3 ± 5.4† 27.8 ± 5.5 41.0 ± 4.6†
ATP levels were normalized to tissue weight. Percent control levels were determined by dividing all samples by the mean of the Crt +/y mice for the specific tissue studied. Data are shown
as mean ± SEM (n = 6-8).
†p  0.05 vs Slc6a8+/y.
‡p  0.05 DCE-ME vs vehicle.
DCE-ME: Dodecylcreatine ester-microemulsion; SEM: Standard error of the mean.
Intranasal administration of DCE-ME treatment improves object recognition learning in Slc6a8-/y
mice
For the discrimination index, there was a main effect of group (F [2,21] = 7.03, p < 0.01). Multiple comparison
analysis showed that DCE-ME treated Slc6a8-/y mice spent more time observing the novel object compared with
vehicle-treated Slc6a8-/y mice (p < 0.05) but less time with the novel object compared with Slc6a8+/y mice
(p < 0.05) (Figure 3). It is unlikely that changes in overall activity levels were responsible for the increase time
spent with the novel object, as there was no effect of treatment on distance traveled in the arena during testing
(F[2,20] = 2.374, p = 0.12; mean ± standard error of the mean: WT: 15.0 ± 1.8; VEH: 18.1 ± 1.8; DCE-ME:
20.3 ± 1.5). The rescue of cognitive deficit in Slc6a8-/y mice was associated with an increase of creatine in the
different brain regions as shown by experiments carried out during DCE-ME optimization (Supplementary Figure
1). Interestingly, while Cr was increased in most of the brain regions, examined ATP was only increased in the
striatum (Table 2). Since there is a wealth evidence that long-term potentiation (LTP) underlies certain form of
memory [6], we were interested in the expression of LTP biomarkers after IN DCE-ME administration in Slc6a8-/y
mice. While while Bdnf expression does not reached significance, a tremendous increased expression of Psd95 and
Creb was observed following DCE-ME treatment of Slc6a8-/y mice (Figure 4A).
Discussion
CTD is an X-linked intellectual disability caused by mutations of creatine transporter leading to the perturbation
of neuronal function. Based on our previous established relationship [13], DCE is one the most likely Cr derivatives
diffusing passively through the cell membrane. These facts makes DCE as an ideal leader molecule for in vivo
testing. In the present paper, we have demonstrated that following ICV administration DCE was able to diffuse
through different brain regions; and turned into Cr in brain cells and improved cognitive function in Slc6a8-/y
mice. The rescue of NOR deficits with a modest increase in Cr levels is in agreement with data from Kurosawa
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Figure 2. Improved object recognition memory in Slc6a8-/y mice and creatine content in different brain regions
after intracerebroventricular treatment with dodecylcreatine ester (cont.). (A) Novel object recognition tests were
conducted 1 h after familiarization in Slc6a8-/y and Slc6a8+/y (n = eight animal/group) mice treated for 5 days with
vehicle or DCE. The discrimination index was calculated as the difference between new and familiar object
exploration times divided by total time spent observing both objects. Experimental comparisons with multiple groups
were analyzed using a one-way ANOVA with the false discovery rate method of Benjamini, Kreiger and Yekutieli used
for post hoc analysis. Data are mean ± standard error of the mean. (B) Creatine content in different brain regions of
Slc6a8+/y and Slc6a8-/y mice (n = 4) after intracerebroventricular administration of DCE measured by LC-MS/MS. Data
are mean ± standard error of the mean. Mann–Whitney test.
*p ≤ 0.05.
DCE: Dodecylcreatine ester.
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Figure 3. Improved object recognition memory in
Slc6a8-/y mice after nasal administration of
dodecylcreatine ester-microemulsion. Novel object
recognition tests were conducted 1 h after
familiarization in Slc6a8-/y and Slc6a8+/y (n = eight
animal/group) mice before and after 10 days of
intranasal treatment with vehicle or DCE-ME. Data were
analyzed using one-way ANOVA with the false discovery
rate method of Benjamini, Kreiger and Yekutieli used for
post hoc analysis. Data are mean ± standard error of the
mean.
*p ≤ 0.05.
DCE-ME: Dodecylcreatine ester-microemulsion.
et al., who showed a restoration of NOR learning following cCr treatment [12]. The cCr levels in the brain of
Slc6a8-deficient mice were approximately 50% of WT. Further, the total of Cr plus cCr in Slc6a8-deficient mice
were approximately 25% of WT Cr + cCr. These facts suggest that restoring Cr levels to approximately 25% can
preserve NOR learning. This is supported by data from the heterozygous Slc6a8 females, who have 50% of the
brain Cr compared with WT mice and do not show NOR deficits [19].
For the pediatric clinical perspectives and keeping in mind that we expect in the future to treat patients showing
moderate to severe intellectual disability, behavioral disorder such as attention deficit, hyperactivity disorder or
autistic behavior, and occasionally epilepsy, we focused on the noninvasive therapeutic approach. We report in this
paper and for the first time a new therapeutic approach based on a ME loaded with DCE for nasal delivery of
DCE into the brain. This new formulation DCE-ME was well characterized. Due to its amphiphilic character,
DCE was efficiently encapsulated into the optimized ME with an encapsulation efficiency of about 85%. The
resulting delivery particles had a size around 150 nm and a positive charge stable which accounts for in vivo cellular
uptake. Indeed, fatty acids present in Maisine R© CC reduce ζ potential and suppress coalescence which provides a
supplementary stabilizing effect for ME. Since our formulation was intended for IN administration, the inclusion
of a biocompatible permeation enhancer such as DHA was of interest. This compound is also known for its role in
neural function and is also involved in multiple brain functions including cell membrane fluidity, receptor affinity
and modulation of signal transduction molecules [15,24,25].
Our ME drug delivery system was applied for the treatment of homozygous SLC6A8-/y mice following IN
administration. Nasal administration of DCE-ME highlighted the interest of DCE-ME in improving cognitive
deficit. The improvement of cognitive function is certainly due to the transport of DCE-loaded vesicles by either
direct pathway through the olfactory bulbs or trigeminal nerve or either by the indirect pathway involving transport
of DCE-loaded vesicles via lymphatic system. Once in the brain, DCE-loaded vesicles could be transported to
various brain regions by extraneuronal, intraneuronal or transneuronal transport. The rescue of cognitive deficit in
Slc6a8-/y mice was associated with an increase increasing of creatine in the different brain regions. These facts are in
agreement with data from Kurosawa et al., who showed a restoration of NOR learning following cCr treatment [12].
In addition, our data suggest that ATP-generated oxidative phosphorylation or glycolysis is transferred to Cr to
form pools of phospho-Cr. The phosphate group can then be transferred to ADP at the sites of ATP consumption,
providing a rapid energy replenishment. These results are in agreement with previous observations [5]. Interestingly,
while Cr was increased in most of the brain regions examined, ATP was only increased in the striatum. While the
mechanism that underlies this is unknown, it could reflect the different metabolic demands of neurons from each
region. While the method used to collect tissue may not adequately represent the physiological levels of ATP, great
care was taken to ensure that the tissue taken from each mouse was treated similarly; therefore, ATP hydrolysis
should be equal in across subjects.
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Figure 4. Nasal administration of dodecylcreatine ester-microemulsion rescue BDNF levels in the striatum of
Scl6a8-/y mice. (A) Real-time PCR shows that in the striatum of Scl6a8-/y mice, ME increases PSD95, CREB and BDNF
levels compared with nontreated Scl6a8-/y mice. One-way ANOVA with the Tukey’s multiple comparison test for post
hoc analysis were performed and ***p < 0.001 indicates significant differences between nontreated Scl6a8-/y mice
and treated Scl6a8-/y mice or between Scl6a8+/y mice and nontreated Scl6a8-/y mice. Data are represent
mean ± standard error of the mean (n = 3–6). (B) Schematic representation of regulation of synaptic markers in the
striatum brain region implicated in novelobject recognition memory. The increased expression of Psd95, Creb and
Bdnf participate in the restoration of cognitive function in the creatine transporter deficiency mice model.
***p < 0.001.
DCE-ME: Dodecylcreatine ester-microemulsion.
10.2217/nnm-2019-0059 Nanomedicine (Lond.) (Epub ahead of print) future science group
Neurotherapeutics for CTD Research Article
Literature highlighted the role of glutamate uptake in synaptic vesicles and through their action on postsynaptic
receptors affect signal transduction processes involved in long-term potentiation (LTP) [5,6]. Increased expression
of LTP biomarkers Psd95, Creb and Bdnf was observed following DCE-ME treatment of Slc6a8-/y mice. Figure 4B
proposes a possible mechanism of action at the synaptic terminus in brain cells after DCE-ME IN administration
in Slc6a8-/y mice. Our findings suggest that following the IN administration of our formulation, an increase of
synaptic markers could be achieved in the synapsis terminals and thus improving the cognitive function of Slc6a8-/y
mice. These results are in agreement with the role of LTP biomarkers in amelioration of learning memory and
deficits in different animal models of neurodegenerative diseases [26,27].
There is no current treatment to improve the neurodevelopmental delays or increase creatine in brain in males
with CTD. We report for the first time that DCE treatment using intranasal treatment of ME drug delivery system
is an attractive approach to circumvent the BBB and to restore the cognitive function in homozygous SLC6A8-/y
mice attributable to targeting Cr in brain cells. These results highlight the potential value of DCE-ME as promising
therapy for CTD.
Future perspective
This study reports the first in vivo proof of concept for the treatment of the CTD by overcoming the BBB
by the rational design of DCE nanoemulsion. Further studies are mandatory before evaluating the therapeutic
efficiency of this strategy in CTD patients. We believe that the replenishment of creatine and consequently the
improvement of cognitive function is due to the transport of DCE loaded vesicles by either direct pathway through
the olfactory bulbs or trigeminal nerve or either by the indirect pathway involving transport of DCE-loaded vesicles
via lymphatic system. Once in the brain, DCE-loaded vesicles could be transported to various brain regions by
extraneuronal, intraneuronal or transneuronal transport. As perspective, experiments will be undertaken to formally
confirm our hypothesis. In this context the incorporation of high sensitivity DCE-radiolabeled compound into the
nano-engineered delivery system will help for in vivo pharmacokinetic profile of DCE-ME delivery system after
nasal administration to Ko mice. DCE will be quantify by ex vivo radio-imaging, with or without MS coupling.
In addition, since CTD is a progressive metabolic disorder, we will perform a longitudinal investigation of
neurochemical and behavioral readouts including investigations of synaptic brain plasticity biomarkers in animals
of different ages intranasally treated with different DCE-ME doses. This will help for the determination of the
therapeutic windows of our neurotherapeutics for the treatment of CTD.
Finally, toxicology reglementary studies will yield a strong therapeutic perspective for the treatment of CTD.
Summary points
• We have demonstrated that intracerebroventricular administration of dodecyl creatine ester (DCE) alone increase
creatine levels in several brain regions of Slc6a8-/y mice.
• We have demonstrated that intracerebroventricular administration of DCE improve novel object recognition
memory in Slc6a8-/y mice.
• We focus on the preclinical development of a new therapeutic approach based on a microemulsion (ME) as drug
delivery system loaded with DCE (DCE-ME) on the treatment of Slc6a8 knockout (Slc6a8-/y) mice.
• DCE-ME formed monodispersed populations polydispersity index (PDI ≤0.2) with a mean size of around 150 nm
and a positive charge surface.
• Due to its amphiphilic character, DCE was efficiently encapsulated into the optimized ME with an encapsulation
efficiency of about 85%.
• Intranasal treatment with DCE-ME for 10 days improved novel object recognition performance deficits in
Slc6a8-/y mice.
• These results highlight the potential value of DCE-ME as promising therapy for creatine transporter deficiency.
• Future pharmacology and toxicology studies will yield a strong therapeutic perspectives for the treatment of
creatine transporter deficiency.
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